VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/32205092/

⇱ TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib - PubMed

Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
👁 Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

👁 Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Keywords: COVID-19; Cytokine storm; JAK2 inhibitor; SARS-CoV-2; TH17.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All authors have no conflicts of interest to declare.

Figures

👁 Figure 1
Figure 1
Quantitative RT-PCR of cytokine mRNAs in murine TH17 cells. In vitro differentiated TH17 cells were activated with plate-bound anti-CD3 and anti-CD28 and treated with or without IL-23 in the presence of 2 μM Fedratinib (Fedr) or a vehicle (saline) for 4 h. The results were normalized to an internal control Actb and the vehicle treatment was set as 1. Data (mean and s.d.) represent 2 experiments (N = 3 in each group). Two side student T test, ∗, p ≤ 0.05; ∗∗, p ≤ 0.005.

References

    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
    1. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30076-X. [Epub ahead of print] - DOI - PMC - PubMed
    1. Zenewicz L.A. IL-22: there is a gap in our knowledge. Immunohorizons. 2018;2:198–207. - PMC - PubMed
    1. Tse G.M., To K.F., Chan P.K., Lo A.W., Ng K.C., Wu A. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS) J Clin Pathol. 2004;57:260–265. - PMC - PubMed
    1. Faure E., Poissy J., Goffard A., Fournier C., Kipnis E., Titecat M. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014;9:e88716. - PMC - PubMed

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
👁 Elsevier Science full text link
Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.